膜杰作
Star Staining
描述（Description）
The Human Activin RII (Luc) HEK293 Reporter Cell was engineered to express Smad signaling response element driving luciferase expressing systems. When stimulated with multiple ligands, including activin, myostatin and GDF-11, receptor-mediated signaling can drive Smad-mediated luminescence. Neutralization of biological effect of the ligand-receptor interaction by corresponding antibody results in a decrease in luminescence.
应用说明（Application）
• Screen for neutralizing antibodies blocking the ligand-receptor interaction.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL)
培养基（Culture Medium）
DMEM + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Application
Inhibition of human GDF-8 protein-induced reporter activity by anti-Activin RII neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human GDF-8 protein with a final concentration of 0.3 μg/mL. The EC50 of anti-Activin RII neutralizing antibody (Bimagrumab) is approximately 0.002109 μg/mL.
Protocol
Inhibition of human GDF-11 protein-induced reporter activity by anti-Activin RII neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human GDF-11 protein with a final concentration of 0.3 μg/mL. The EC50 of anti-Activin RII neutralizing antibody (Bimagrumab) is approximately 0.005157 μg/mL.
Protocol
Inhibition of human Activin A protein-induced reporter activity by anti-Activin RII neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human Activin A protein (Cat.No.ACA-H421b) with a final concentration of 0.01 μg/mL. The EC50 of anti-Activin RII neutralizing antibody (Bimagrumab) is approximately 0.04982 μg/mL.
Protocol
Signaling Bioassay
Response to human Activin A protein (RLU).
The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human Activin A protein (Cat.No.ACA-H421b). The EC50 was approximately 0.00497 μg/mL.
Protocol
Response to human Activin A protein (FOLD).
The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human Activin A protein (Cat.No.ACA-H421b). The max induction fold was approximately 172.
.
Protocol
Response to human GDF-11 protein (RLU).
The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human GDF-11 protein. The EC50 was approximately 0.2071 μg/mL.
Protocol
Response to human GDF-11 protein (FOLD).
The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human GDF-11 protein (Cat.No.ACA-H421b). The max induction fold was approximately 192.
Protocol
Response to human GDF-8 protein protein (RLU).
The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human GDF-8 protein. The EC50 was approximately 1.387 μg/mL.
Protocol
Response to human GDF-8 protein protein (FOLD).
The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human GDF-8 protein. The max induction fold was approximately 150.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
Actvin and myostatin bind to activin type II receptors (ActRIIA and ActRIIB), and the glycine–serine-rich domains of type I receptors are phosphorylated by type II receptors. Activin enhances follicle-stimulating hormone biosynthesis and secretion and is involved in apoptosis, fibrosis, inflammation, and neurogenesis.
License Disclosure
This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
